Turning to solid tumors, cell therapy play Triumvira earns syndicate’s $55M vote of confidence

Since its 2015 launch, Triumvira has changed CEOs once, developed a third iteration of its engineered T cell therapeutics platform, and deprioritized a former lead program for blood cancer after it reached the IND stage. Now, the start-up has collected a $55 million series A round to take its first two programs into the clinic to treat solid tumors.

Leaps by Bayer and Northpond Ventures led the round, which will support clinical development of two cell therapies based on Triumvira Immunologics Inc.’s T cell Antigen Couplers (TAC) platform. Leaps, the venture arm affiliated with Bayer AG (Xetra:BAYN), invests in early-stage platform technologies...